Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jan;45(1):159-166.
doi: 10.1007/s40618-021-01630-4. Epub 2021 Jul 3.

Mechanisms of acute hypercalcemia in pediatric patients following the interruption of Denosumab

A Deodati  1 , D Fintini  1 , E Levtchenko  2 , M Rossi  3 , G Ubertini  1 , H Segers  2 , G Battafarano  3 , M Cappa  1 , A Del Fattore  4
Affiliations
Case Reports

Mechanisms of acute hypercalcemia in pediatric patients following the interruption of Denosumab

A Deodati et al. J Endocrinol Invest. 2022 Jan.

Abstract

Purpose: Denosumab is a fully human monoclonal anti-RANK-L antibody that is clinically used to counteract the bone loss induced by exacerbated osteoclast activity. Indeed, its binding to RANK-L prevents the interaction RANK-L/receptor RANK that is essential for osteoclastogenesis and bone resorbing activity. Although there are many medications available to treat bone loss diseases, including bisphosphonates, Denosumab is highly effective since it reduces the bone erosion. The use in pediatric patients is safe. However, some concerns are related to the interruption of the treatment. Indeed, in this study, we reported hypercalcemia in two pediatric patients and alterations of circulating osteoclast precursors.

Methods: Peripheral Blood Mononuclear Cells (PBMC) were isolated from two pediatric patients with hypercalcemia after Denosumab interruption and from 10 controls. Cytofluorimetric analysis and in vitro osteoclastogenesis experiments were performed.

Results: Increase of CD16-CD14+CD11b+ cells was revealed in PBMC from patients reflecting the enhanced in vitro osteoclastogenesis.

Conclusion: Our data suggest that precautions must be taken when Denosumab therapy is interrupted and gradual decrease of dose and/or timing of treatment should be performed. To prevent the onset of hypercalcemia that could be in the discontinuation phase, cytofluorimetric analysis of PBMC should be performed to evaluate osteoclast precursors.

Keywords: Denosumab; Hypercalcemia; Osteoclast; Osteoclast precursor.

PubMed Disclaimer

References

    1. Hofbauer LC, Heufelder AE (2001) Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med (Berl) 79(5–6):243–253. https://doi.org/10.1007/s001090100226 - DOI
    1. Kearns AE, Khosla S, Kostenuik PJ (2008) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29(2):155–192. https://doi.org/10.1210/er.2007-0014 - DOI - PubMed
    1. Ono T, Hayashi M, Sasaki F, Nakashima T (2020) RANKL biology: bone metabolism, the immune system, and beyond. Inflamm Regen 40:2. https://doi.org/10.1186/s41232-019-0111-3 - DOI - PubMed - PMC
    1. Ahern E, Smyth MJ, Dougall WC, Teng MWL (2018) Roles of the RANKL-RANK axis in antitumour immunity—implications for therapy. Nat Rev Clin Oncol 15(11):676–693. https://doi.org/10.1038/s41571-018-0095-y - DOI - PubMed
    1. Xiong J, Cawley K, Piemontese M, Fujiwara Y, Zhao H, Goellner JJ, O’Brien CA (2018) Soluble RANKL contributes to osteoclast formation in adult mice but not ovariectomy-induced bone loss. Nat Commun 9(1):2909. https://doi.org/10.1038/s41467-018-05244-y - DOI - PubMed - PMC

Publication types

MeSH terms

LinkOut - more resources